Merck $2.2 billion acquisition of Peloton Therapeutics

Overview:

• Merck has acquired Peloton Pharmaceuticals in a $2.2 billion deal. 
• Peloton is a clinical-stage biopharmaceutical company that focuses on cancer treatments. 
• Merck paid $1.05 billion in cash, with another $1.15 billion to be added based on certain sales and regulatory criteria. 
• Credit Suisse acted as financial adviser for Merck and Centerview Partners advised Peloton. 
• The transaction is expected to close in the third quarter of 2019. 

Kurt Stumpo - US Editor